Stroke spasm
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Voluntary participation, the subjects have no mental disorders, can fully understand and cooperate with this trial, and are willing to sign the consent form. If the subjects are hemiplegic on the dominant side and unable to sign, their legal representatives can sign the informed consent form with their consent. 2.They meet the diagnostic criteria for stroke formulated by the Fourth National Academic Conference on Cerebrovascular Diseases and have a clear diagnosis confirmed by head CT or MRI. 3.They have unilateral hemiplegia, with a modified Ashworth scale score of the ankle plantar flexor muscle group on the hemiplegic side greater than grade 1, and normal muscle tone on the non-hemiplegic side. 4.They have had their first stroke or have had lacunar infarction in the past without sequelae. 5.The course of stroke in the subjects is 2 months to 1 year, and the condition is stable. 6.Age range: 18 to 80 years old, gender and handedness are not limited. 7.Consciousness is clear, auditory comprehension is basically normal, and they can cooperate with treatment and assessment. 8.There is no obvious discomfort during changes in body position (the subjects are assisted by two people to transfer from bed to wheelchair), blood pressure, heart rate, and breathing are stable, and there is no pain, chest tightness, shortness of breath, dizziness, headache or other discomfort. They can tolerate the supine or prone position for 30 minutes. 9.They have a certain walking ability with or without the assistance of a walking aid.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of diabetes and other conditions that may cause peripheral nerve damage, Parkinson's disease and other conditions that may cause high muscle tone, and those with concurrent muscle diseases; 2.Those with severe cognitive, speech, vision, hearing impairments (such as deaf-mutes) or mental disorders that affect examination and treatment; 3.Those with concurrent tumors, severe respiratory, heart, liver, kidney, endocrine and hematopoietic system diseases, such as patients with congestive heart failure, uncontrolled hypertension, blood pressure higher than 140/90mmHg, active liver disease, liver and kidney insufficiency; 4.Those with joint disorders in the measured joint itself (such as severe infection, contracture, joint surgery, rheumatoid or rheumatoid arthritis); 5.Those with contraindications for nerve electrophysiology, ultrasound assessment, and extracorporeal shock wave therapy (such as bleeding disorders, patients with coagulation dysfunction that may cause local tissue bleeding, presence of thrombosis in the treatment area, severe cognitive and mental disorders, skin damage, fever, history of tumors, pregnancy, lactation, etc.); 6.Those taking drugs that affect muscle tone, and those who have received botulinum toxin injections within the last 3 months; 7.Those currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Ashworth scale score ;Fugl-Meyer Motor Function scale score (Lower limbs); | — |
Secondary
| Measure | Time frame |
|---|---|
| Mofidied Tardieu scale score;Barthel index scale score ;10 meter pace test;Neurophysiological examination (H-reflex of the tibial nerve); | — |
Countries
China
Contacts
Huashan Hospital affiliated to Fudan University